Six target genes were subjected to protein validation: GPR116, NPY and PLA2G7, three genes over-expressed in ERG+ tissues, and AZGP1, HPGD and TFF3, three genes down-regulated in ERG+ prostate cancer tissues. The gene discussed is HPGD; the disease is prostate cancer.